

Resource Summary Report

Generated by [dkNET](#) on Sep 19, 2026

CD45

RRID:AB_2744404

Type: Antibody

Proper Citation

BD Biosciences Cat# 564357, RRID:AB_2744404

Antibody Information

URL: http://antibodyregistry.org/AB_2744404

Proper Citation: BD Biosciences Cat# 564357, RRID:AB_2744404

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: HI30

Antibody ID: AB_2744404

Vendor: BD Biosciences

Catalog Number: 564357

Alternative Catalog Numbers: 564358

Record Creation Time: 20231110T033442+0000

Record Last Update: 20260901T020847+0000

Ratings and Alerts

No rating or validation information has been found for CD45.

No alerts have been found for CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hill EJ, et al. (2026) Temporal regulation of human reactive astrocytes reveals their capacity for antigen presentation. *Neuron*, 114(13), 2331.

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. *Cell stem cell*, 33(6), 982.

You JE, et al. (2025) Secreted AZGP1 induced by 5-FU binds to PD-L1 and promotes apoptosis in cholangiocarcinoma. *Molecular medicine (Cambridge, Mass.)*, 31(1), 295.

Mei Y, et al. (2024) IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment. *Cell reports*, 43(3), 113835.

Diepstraten ST, et al. (2024) Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. *Cancer cell*, 42(5), 850.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. *Cancer immunology research*, 12(4), 491.

Ma R, et al. (2024) Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. *Cell reports. Medicine*, 5(7), 101628.

Pelletier J, et al. (2023) Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation. *iScience*, 26(4), 106385.

Demaria O, et al. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. *Cell reports. Medicine*, 3(10), 100783.